Concepedia
Statistics
Publications
36
Citations
5.5K
H-Index
29
Active since
2006
Affiliations
Epizyme (United States)(Current)
University of North Carolina at Chapel Hill
Ribon Therapeutics (United States)
University of Toronto
Structural Genomics Consortium
Tim J. Wigle is an author at Epizyme (United States) specializing in molecular biology, drug discovery, and medicine.
Publications per year
2006–2021
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle et al. · Proceedings of the National Academy of Sciences · 2013 · 782 citations · Full text
Medicine, Oncology, Pharmacology +16
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic et al. · Nature Chemical Biology · 2012 · 761 citations
Medicine, Molecular Biology, Oncology +12
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations
Medicine, Medicinal Chemistry, Pharmacology +8
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
Masoud Vedadi, Dalia Baršytė-Lovejoy, Feng Liu et al. · Nature Chemical Biology · 2011 · 531 citations
Life Sciences, Biochemistry, Pharmacology +9
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i> -Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima et al. · Molecular Cancer Therapeutics · 2014 · 522 citations
Medicine, Oncology, Pharmacology +14
1–5 of 36